Amphastar Pharmaceuticals EBITDA Margin 2012-2025 | AMPH
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Amphastar Pharmaceuticals (AMPH) over the last 10 years. The current EBITDA margin for Amphastar Pharmaceuticals as of December 31, 2025 is .
| Amphastar Pharmaceuticals EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-12-31 | $0.72B | $0.20B | 27.92% |
| 2025-09-30 | $0.72B | $0.21B | 28.87% |
| 2025-06-30 | $0.72B | $0.24B | 33.20% |
| 2025-03-31 | $0.73B | $0.25B | 34.61% |
| 2024-12-31 | $0.73B | $0.26B | 36.07% |
| 2024-09-30 | $0.72B | $0.28B | 38.04% |
| 2024-06-30 | $0.71B | $0.30B | 41.37% |
| 2024-03-31 | $0.68B | $0.27B | 39.88% |
| 2023-12-31 | $0.65B | $0.25B | 38.29% |
| 2023-09-30 | $0.60B | $0.22B | 36.71% |
| 2023-06-30 | $0.54B | $0.16B | 29.57% |
| 2023-03-31 | $0.52B | $0.15B | 27.99% |
| 2022-12-31 | $0.50B | $0.13B | 26.71% |
| 2022-09-30 | $0.48B | $0.12B | 24.59% |
| 2022-06-30 | $0.48B | $0.12B | 25.00% |
| 2022-03-31 | $0.46B | $0.11B | 23.08% |
| 2021-12-31 | $0.44B | $0.09B | 21.23% |
| 2021-09-30 | $0.41B | $0.07B | 17.43% |
| 2021-06-30 | $0.38B | $0.05B | 13.28% |
| 2021-03-31 | $0.37B | $0.04B | 9.78% |
| 2020-12-31 | $0.35B | $0.03B | 9.14% |
| 2020-09-30 | $0.34B | $0.03B | 8.31% |
| 2020-06-30 | $0.33B | $0.03B | 7.78% |
| 2020-03-31 | $0.33B | $0.03B | 8.87% |
| 2019-12-31 | $0.32B | $0.02B | 5.59% |
| 2019-09-30 | $0.33B | $0.02B | 5.78% |
| 2019-06-30 | $0.33B | $0.02B | 5.85% |
| 2019-03-31 | $0.32B | $0.02B | 4.73% |
| 2018-12-31 | $0.30B | $0.01B | 2.71% |
| 2018-09-30 | $0.27B | $0.00B | 1.51% |
| 2018-06-30 | $0.25B | $0.00B | -0.81% |
| 2018-03-31 | $0.24B | $0.00B | 1.24% |
| 2017-12-31 | $0.24B | $0.01B | 5.83% |
| 2017-09-30 | $0.24B | $0.01B | 4.51% |
| 2017-06-30 | $0.25B | $0.02B | 8.00% |
| 2017-03-31 | $0.25B | $0.03B | 11.07% |
| 2016-12-31 | $0.26B | $0.03B | 12.16% |
| 2016-09-30 | $0.27B | $0.05B | 18.66% |
| 2016-06-30 | $0.27B | $0.04B | 14.93% |
| 2016-03-31 | $0.25B | $0.02B | 7.48% |
| 2015-12-31 | $0.25B | $0.01B | 2.78% |
| 2015-09-30 | $0.23B | $-0.01B | -6.06% |
| 2015-06-30 | $0.23B | $-0.02B | -7.93% |
| 2015-03-31 | $0.22B | $-0.01B | -4.05% |
| 2014-12-31 | $0.21B | $0.00B | -1.90% |
| 2014-09-30 | $0.21B | $0.01B | 2.38% |
| 2014-06-30 | $0.21B | $0.01B | 5.74% |
| 2014-03-31 | $0.22B | $0.03B | 11.21% |
| 2013-12-31 | $0.23B | $0.03B | 12.61% |
| 2013-09-30 | $0.23B | $0.08B | 33.04% |
| 2013-06-30 | $0.23B | $0.13B | 57.33% |
| 2013-03-31 | $0.21B | $0.16B | 77.25% |
| 2012-12-31 | $0.20B | $0.20B | 100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.310B | $0.732B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.071B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.806B | 18.36 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Bausch Health Cos (BHC) | Canada | $2.222B | 1.58 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.055B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |